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ReceptorAdeno-associated virus is a promising vector for gene therapy. In the current study, the binding site on AAV
serotype 3B for the heparan sulfate proteoglycan (HSPG) receptor has been characterized. X-ray diffraction
identiﬁed a disaccharide binding site at the most positively charged region on the virus surface. The
contributions of basic amino acids at this and other sites were characterized using site-directed mutagenesis.
Both heparin and cell binding are correlated to positive charge at the disaccharide binding site, and transduc-
tion is signiﬁcantly decreased in AAV-3B vectors mutated at this site to reduce heparin binding. While the
receptor attachment sites of AAV-3B and AAV-2 are both in the general vicinity of the viral spikes, the
exact amino acids that participate in electrostatic interactions are distinct. Diversity in the mechanisms of
cell attachment by AAV serotypes will be an important consideration for the rational design of improved
gene therapy vectors.
© 2011 Elsevier Inc. All rights reserved.Adeno-associated virus (AAV) is a small (~25 nm) parvovirus,
with an ~4.7 kb ssDNA genome packaged inside a non-enveloped
capsid of T=1 icosahedral (60-fold) symmetry (Caspar and Klug,
1962; Xie et al., 2002). As a non-pathogenic virus, AAV has become
a leading candidate vector for human gene therapy (Hildinger and
Auricchio, 2004). Several naturally occurring serotypes of AAV have
been identiﬁed, each having broad, but distinct tissue speciﬁcity
(Buning et al., 2004; Mitchell et al., 2010). In addition to having
broad tropism, AAV vectors are often neutralized in individuals previ-
ously exposed to virus or vector (Zaiss and Muruve, 2005). Knowl-
edge of the structure and infectious pathway of AAV serotype
capsids provides a template to engineer vectors that more speciﬁcally
target diseased tissues, and to engineer neutralization escape variants
that remain viable in cell entry (Buning et al., 2003; Flotte, 2004;
Mitchell et al., 2010).
Prior to cell entry, AAV serotype 3 (AAV-3) attaches to target cells
by binding heparan sulfate proteoglycan (HSPG) (Handa et al., 2000;
Rabinowitz et al., 2002), but few details are known. In contrast, the
binding site on AAV-2 for HSPG (or its analog heparin) has been
well characterized, and is centered at Arg585 and Arg588 on the sides
of the 3-fold proximal spikes (Kern et al., 2003; O'Donnell et al.,AAV, adeno-associated virus;
metry; WT, wild type; ELISA,
scent protein.
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n).
rights reserved.2009; Opie et al., 2003). Intriguingly, these residues are not conserved
in AAV-3, and the determinants of receptor binding by AAV-3 remain
unknown.
An understanding of the diversity in AAV-heparin interactions will
advance our fundamental understanding of receptor attachment.
AAV-3 is of particular interest because of its ability to transduce
hematopoietic cells (Handa et al., 2000) and liver cancer cells
(Glushakova et al., 2009) relatively efﬁciently. However, AAV-3
transduction levels are low for most cell types (Van Vliet et al.,
2008). For AAV-2, heparin binding correlates closely with tissue
speciﬁcity (Asokan et al., 2010; Grimm et al., 2008). In addition, the
heparin binding site on AAV-2 can be replaced with peptide ligands
to efﬁciently re-target vectors to desired tissues (Perabo et al., 2006;
Shi and Bartlett, 2003; Shi et al., 2006). Similarly, detailed knowledge
of receptor interactions by this serotype could increase its therapeutic
potential.
We recently determined the crystal structure of AAV-3B (Lerch
et al., 2010), a minor variant of AAV-3. The overall capsid struc-
ture is similar to that of other AAV serotypes which all have
spike-like protrusions surrounding the 3-fold axes. Despite the
structural similarity, the electrostatic surface potential of AAV-3B
is quite different from that of other serotypes in the region corre-
sponding to the AAV-2 HSPG-binding site. This has functional
implications, as HSPG and heparin are negatively charged and
typically form ionic interactions with basic regions on the surface
of heparan-binding proteins (Conrad, 1998). Two regions near the
spikes that are positively charged and unique to AAV-3B (Lerch
et al., 2010), could, we hypothesized, facilitate receptor interac-
tions in AAV-3B.
Fig. 1. Identiﬁcation of potential heparin binding residues on AAV-3B. Two views near
the 3-fold promixal spikes of AAV-3B are shown. (A) The spike-like protrusions of
AAV-3B viewed down a 3-fold symmetry axis. A ribbon representation of the AAV-3B
capsid can be seen beneath the translucent molecular surface, which is colored by elec-
trostatic surface potential (blue = positive; red= negative). Two regions near residues
Arg447 and Arg594 have strong positive surface charge and were identiﬁed as candidate
receptor binding sites. (B) Structural overlay of a single spike from AAV-3B (green) and
AAV-2 (magenta). Arg447 is conserved in AAV-2, but forms a salt bridge with Glu499
(dashed line). Asn500 is the equivalent residue in AAV-3B and, as a neutral amino acid,
does not pair with Arg447, leaving a stronger positive surface charge at this site. On
the left, differences in the AAV-2 HSPG site are highlighted with Arg585 and Arg588 of
AAV-2 replaced by Ser586 and Thr589 in AAV-3B.
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sulfate analogs were investigated. The location of the receptor
binding site was determined from crystallographic data from a
complex of AAV-3B and an HSPG analog. AAV-3B capsid mutants
were then used to (1) conﬁrm the structural identiﬁcation of the
heparin binding site, (2) correlate heparin and cell binding to positive
charge on the capsid surface, and (3) demonstrate the requirement of
the heparin binding site for cellular transduction.
Results
Prediction of potential heparin binding residues
From the 2.6 Å crystal structure of AAV-3B (Lerch et al., 2010),
candidate receptor binding sites were identiﬁed. Speciﬁcally, the
electrostatic surface potential shows positively-charged regions near
the 3-fold proximal spikes that are unique to AAV-3B (Fig. 1A).
Heparin binding proteins typically interact with their ligands through
one or a cluster of basic residues. One of the positively charged
regions is centered on Arg447. Arg447 is conserved in several other
AAV serotypes, many of which do not bind heparin. In AAV-2,
Arg447 is not involved in heparin interactions. In fact, its charge is
neutralized by a salt-bridge with Glu499 (Fig. 1B). In AAV-3B, Glu499
is replaced by Asn500, so the region is more positively charged. A
second positively charged region is centered on Arg594, the only
surface-exposed basic amino acid in AAV-3B that is not conserved in
other serotypes. Three Arg594 residues from adjacent subunits cluster
at the 3-fold icosahedral axis to form the region of strongest positive
charge on the AAV-3B surface (Fig. 1A).
Crystallographic identiﬁcation of a receptor binding locus on AAV-3B
Diffraction data were collected from AAV-3B crystals grown in the
presence of the heparin analog sucrose octasulfate (SOS). SOS has
been used previously in structural studies of heparin-binding
proteins (Innis and Hyvonen, 2003). The best crystal diffracted X-
rays to 6.5 Å resolution and belongs to space group F4132. Resolution
of 6.5 Å is not sufﬁcient to build atomic models, but it sufﬁces to
identify a ligand-binding site on a structure determined at 2.6 Å
resolution, especially with the high quality maps available following
5-fold non-crystallographic symmetry averaging (Badger et al.,
1988). The 2.6 Å native AAV-3B structure (Lerch et al., 2010) could
be superimposed accurately on the SOS complex map by alignment
of their icosahedral symmetry axes with no degrees of freedom (see
Materials and methods). In fact, without any atomic reﬁnement
(which would be susceptible to over-ﬁtting at 6.5 Å resolution), the
native AAV-3B structure yields Rcryst/Rfree of 0.28/0.27 when
compared to the diffraction data of the SOS complex (Table 1).
A minimally biased maximum likelihood difference map, averaged
according to the 5-fold non-crystallographic symmetry (NCS), was
calculated using Fourier coefﬁcients of mFo−DFc and model phases,
φc, where Fo and Fc are the observed and model structure amplitudes,
m is the ﬁgure of merit weight, and D accounts for model errors
(Read, 1986). A strong positive peak, 10σ above the mean density,
signiﬁed something present in the crystals of SOS complex, but absent
from the atomic model of uncomplexed virus. It was positioned
between the spikes above the outer surface of the capsid. The density
is centered on a viral 3-fold axis above the cluster of three Arg594
residues from neighboring capsid subunits (Fig. 2) that form the
most positive region on the viral surface (see above). The peak is
centered ~7 Å from the Nω atoms of Arg594 and can accommodate
one SOS molecule. Manually modeling with SOS places several sulfate
groups within 3–5 Å of Arg594, i.e. close enough for an ionic interac-
tion. The density is located on a 3-fold symmetry axis, and therefore
represents a mixture of 3 SOS orientations, precluding detailed
modeling. Thus, corroborating experimental evidence would besought (following sections) to characterize independently the func-
tional signiﬁcance of residues implicated by the low resolution
crystallography.
Other features in the difference map were considered. A 10σ peak
in the difference map near the tip of the spikes is unlikely to be SOS
because: (1) it has an elongated shape, (2) modeling with SOS results
in clashes with protein atoms, and (3) the contact surface is not
positively charged. Locally high B-factors in all AAV structures
indicate that the region is among the most disordered (Govindasamy
et al., 2006; Lerch et al., 2010; Nam et al., 2007; Ng et al., 2010; Xie et
al., 2002). The SOS complex and native AAV-3B crystal forms have
distinct packing interactions at this exposed region of the surface
that affect some, but not all of the NCS-related subunits, likely
Table 1
Summary of diffraction data processing and reﬁnement statistics.
Parameter Data processing
Space group F4132
Unit cell dimensions (Å) a=b=c=608.58
Resolution range (Å)a 80–6.5 (6.61–6.50)
# Observations 370,209
Unique reﬂections 19,447
Redundancy 19.0 (19.6)
Rmerge (%)b 16.9 (53.5)
b I>/bσI> 30.2 (7.5)
Completeness (%) 99.9 (100)
cRcryst/Rfree 0.278/0.269
a Numbers in parentheses are values in highest resolution shell.
b Rmerge=∑hkl∑i|Ii(hkl)−b I(hkl)>| /∑hkl∑i Ii(hkl), where Ii(hkl) is the ith obser-
vation of a symmetry equivalent of reﬂection hkl.
c Rfree was calculated with 1953 reﬂections (10% of data) selected randomly.
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to difference peaks at this site. The next strongest peak (8σ) is on
the inner surface on a 5-fold symmetry axis. With noise proportional
to the square root of the local symmetry, the signal/noise of this peak
is just 60% of the Arg594 site (Arnold and Rossmann, 1986). The inner
surface is clearly not the site of receptor binding, and this peak was
interpreted as the highest level of noise. Thus, only the peak near
Arg594 is likely to be SOS.
AAV-3B mutants targeted to disrupt heparin binding
The role of Arg594 and other positively charged residues near AAV-
3B's surface spikes was further investigated by site-directed muta-
genesis. To decrease the surface charge on the side of the AAV-3B
spike, Arg447 was substituted with alanine. Separately, Asn500 was
substituted with glutamate in an attempt to mimic the neutralizing
salt bridge between Glu499 and Arg447 in AAV-2. Targeting the SOS
site observed crystallographically, Arg594 was substituted with either
alanine or glutamate. These AAV-3B mutations (R447A, R594A,
R594E, and N500E) were anticipated to reduce heparin binding.
Heparin binding measurements of wild-type (WT) AAV-3B and
AAV-2 showed that the AAV-3B elutes from a heparin column at
~200 mM lower NaCl than AAV-2 (see Fig. 4A), consistent with
prior observations that AAV-3B has a weaker afﬁnity than AAV-2Fig. 2. The SOS binding site on AAV-3B. Difference (mFo−DFc) electron density (blue
mesh, contoured at 5σ) indicates SOS bound where it can interact electrostatically
with Arg594 in maps calculated using data from the AAV-3B:SOS co-crystals. The densi-
ty can accommodate a single SOS molecule bound to the capsid on the 3-fold symmetry
axis. A ribbon representation of the 2.6 Å AAV-3B structure (Lerch et al., 2010) is over-
layed with a translucent molecular surface.(Lerch et al., 2010; Rabinowitz et al., 2002). The salt concentration
at which heparin binding proteins elute from a heparin column is cor-
related with their heparin binding afﬁnity (Thompson et al., 1994).
Wild-type AAV-3B eluted with the addition of 125–150 mM NaCl
(i.e. at 262–287 mM total [NaCl], including the PBS running buffer;
Fig. 3B). R447A and N500E mutants showed only slightly decreased
afﬁnity, eluting with the addition of 75–125 mM NaCl at a total
[NaCl] of 212–262 mM, indicating at most a minor role in heparin
binding. WT, R447A and N500E were not found in the ﬂow-through
and column wash fractions. By contrast, mutants R594A and R594E
were found only in the ﬂow through and columnwashes (Fig. 3A), in-
dicating that these capsids did not bind to heparin at physiological
ionic strength, and signaling an important role for Arg594 in heparin
binding.
Gain of function AAV-3B mutants
To generate capsids with enhanced heparin binding, Arg585 and
Arg588 (the strongest determinants of heparin binding for AAV2
(Kern et al., 2003; Opie et al., 2003)) were introduced into the equiv-
alent positions in AAV-3B. Mutation at either of the two sites, with
S586R or T589R, was sufﬁcient to raise heparin afﬁnity to AAV-2-
like levels (Fig. 4A), suggesting that other sites (such as Arg594) con-
tribute in AAV-3B. Introduction of both arginines in a double mutant
(S586R/T589R) resulted in a strong increase in heparin afﬁnity over
AAV-2, the capsids eluting with the addition of ~750 mM NaCl at a
total [NaCl] of ~900 mM (Fig. 4).
New constructs were now made with AAV-3B mutations R447A,
R594A, and N500E in the S586R/T589R background. R447A andFig. 3. Heparin-afﬁnity chromatography for AAV-3B mutants designed for diminished
binding. Samples were applied to a heparin column, washed, and eluted in PBS with in-
creasing NaCl concentrations. Capsids were assayed by ELISA, using a capsid-speciﬁc
monoclonal antibody (Grimm et al., 1999). (A) Capsids were detected in the ﬂow-
through and 1st wash fraction only for AAV-3B mutants R594A and R594E, while all
other capsids retained at least some afﬁnity. (B) Elution proﬁles. The [NaCl] added is
shown, and the total [NaCl], including the 137 mM of the PBS running buffer, is shown
in parentheses. AAV-3B bound most tightly, and N500E and R447A eluted in slightly
lower NaCl concentrations, suggesting that these residuesmight play a minor role in hep-
arin binding. R594A or R594E capsidmutantswere not detected in any of the elution frac-
tions, indicating that mutation of Arg594 abrogates heparin binding by AAV-3B.
Fig. 4. Heparin afﬁnity chromatography of AAV-3B mutants with enhanced binding.
The heparin binding residues from AAV-2 (Arg585 and Arg588) were introduced into
the equivalent positions in AAV-3B (replacing Ser586 and Thr589). (A) The heparin bind-
ing afﬁnity of the single S586R and T589R mutants was increased over that of AAV-3B,
and was comparable to that of AAV-2. AAV-3B S586R/T589R shows a striking increase
in heparin binding afﬁnity, presumably due to the combination of heparin binding sites
from two serotypes. (B) AAV-3B S586R/T589R, N500E/S586R/T589R and R447A/
S586R/T589R mutants all bound heparin with high afﬁnity, while R594A/S586R/
T589R showed weaker binding, comparable to that of AAV-2.
Fig. 5. Cell binding by AAV-3B mutants. AAV capsids bound to HeLa cells were detected
by a cell-based ELISA (Kern et al., 2003). (A) AAV-2 capsids bind cells to a greater ex-
tent than WT AAV-3B at similar concentrations. (B) Comparison of cell attachment
for the enhanced-afﬁnity AAV-3B mutants. S586R/T589R, N500E/S586R/T589R and
R447A/S586R/T589R all bound cells comparably and at higher levels than AAV-2. The
R594A/S586R/T589R mutant, however, showed decreased cell binding over the
S586R/T589R mutant. As observed for heparin, R594A/S586R/T589R bound cells at
levels comparable to AAV-2.
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to the S586R/T589R double mutant (Fig. 4B). The triple mutant,
R594A/S586R/T589R, eluted with the addition of 400–600 mM NaCl
(total [NaCl]≈650 mM), which is indistinguishable from AAV-2.
This conﬁrms that the presence of Arg594 in AAV-3B compensates
for the absence of the arginine at 586 and 589 that would be present
in AAV-2.
Cell binding and transduction
While heparin afﬁnity is often used as a proxy, measurement of
cell binding and transduction, where possible, would offer more
functionally relevant characterization. Using methods previously
established for AAV-2 (Kern et al., 2003), HeLa cell binding was ﬁrst
measured for WT AAV-3B and AAV-2 capsids (Fig. 5A) using a range
of virus concentrations from 20 ng/mL to 10 μg/mL (or 3×108 to
3×1011 particles/mL). The concentrations of AAV capsids were deter-
mined by ELISA, using a monoclonal antibody (A20) speciﬁc for
assembled AAV-2 or -3B capsids (Grimm et al., 1999). Equivalent
amounts of AAV capsids were immobilized on a monolayer of HeLa
cells. Capsid particles that remained bound after washing with PBSwere measured by a cell-based ELISA (Kern et al., 2003). WT AAV-2
exhibited stronger binding than WT AAV-3B (Fig. 5A), consistent
with their heparin-binding afﬁnities. Many of the AAV-3B mutants
were available only at concentrations less than the detection limit
for this assay. However, mutants prepared in the high afﬁnity
S586R/T589R background were amenable to measurement. S586R/
T589R exhibited stronger cell binding than WT AAV-3B (Fig. 5B).
Triple mutants R447A/S586R/T589R and N500E/S586R/T589R bound
cells comparably to the S586R/T589R double mutant. R594A/S586R/
T589R bound cells less efﬁciently than the S586R/T589R mutant,
and was comparable to that of AAV-2. All of these cell-binding results
are consistent with the measured heparin afﬁnities and indicate that
Arg594 is a key contributor to cell binding in AAV-3B.
Finally, to establish the role of Arg594 in the infectious pathway of
AAV-3B, transduction assays were performed using WT and R594A
AAV-3B vectors, which package a GFP reporter gene. After 48 h,
HeLa cells transduced with 250 rAAV-3B vector genome-containing
particles (vg) per cell showed strong expression of GFP (Fig. 6B),
with a transduction efﬁciency of 3–4×103 vector genome-
containing particles per transduction event. In contrast, transduction
with R594A rAAV vectors at 250 vg/cell resulted in no GFP expression
(Fig. 6C). At 4-fold higher titer (1000 vg/cell), faint GFP expression
was observed in a small number of cells transduced with R594A
vectors (Fig. 6D), but the transduction efﬁciency was 100× lower
than wild type at ~5×105 vg/transduction. Thus, low levels of cell
entry are measurable even with the R594A mutation, either due to
residual binding or use of an alternative entry pathway (Opie et al.,
2003). However, sharply reduced transduction efﬁciency conﬁrms a
Fig. 6. Arg594 is for a key determinant of AAV-3B transduction. HeLa cells (shown at 200× magniﬁcation) were treated with WT or R594A AAV-3B vectors carrying a GFP gene. GFP
expression was not observed in control cells (A), whereas strong expression was observed in cells transduced with AAV-3B vectors (B). AAV-3B R594A vectors did not transduce
cells at 250 vg/cell (C), but GFP expression was observed in a few cells after treatment with 1000 vg/cell (D, arrow).
10 T.F. Lerch, M.S. Chapman / Virology 423 (2012) 6–13role for Arg594 in cell entry and shows that disruption of the heparin
binding site on AAV-3B results in a decrease in transduction by two
orders of magnitude.
Discussion
A combination of structural and biochemical approaches has been
used to identify a major heparin binding determinant on the surface
of AAV-3B. An absence of negative density in the difference map of
magnitude comparable to the positive SOS peak indicates that large
conformational changes in the capsid are not induced by SOS.
Similarly, there was no evidence of heparin-induced conformational
changes in 8 Å cryo-EM structure of the heparin-AAV2 complex
(O'Donnell et al., 2009). Both studies stand in stark contrast to the
inference of large induced changes from subtle differences in maps
of AAV-2 at much lower (18 Å) resolution (Levy et al., 2009). Unlike
the higher resolution studies, the 18 Å study had to rely on map
features commensurate with experimental noise, a risky endeavor.
However, if the proposed triggering mechanism were a reality, one
would expect it to be conserved across AAV serotypes. The ﬁnding
here that the principal determinants of heparin binding in AAV-2
and AAV-3B are ~20 Å apart makes the proposed triggering
mechanism even less plausible.
In the case of AAV-2, Arg585 and Arg588 are core to receptor inter-
actions, but additional neighboring residues contribute to heparin
binding, as evidenced by less tightly bound heparin polymer that
can be seen at lower contour levels in the AAV-2 complex structure
(O'Donnell et al., 2009). Several of these residues are also conserved
in AAV-3B (including Arg475, Arg485, Arg488, and Lys533). The current
study uses a disaccharide heparin analog and therefore reveals only
the site of tightest binding. It is quite plausible that a polymer could
extend from this site to interact with the conserved basic amino
acids that are part of the AAV-2 binding site. However, our bindingstudies show that the cluster at Arg594 can account for most of the
observed binding under physiological salt concentrations, and that
other residues play a more minor role. What is clear is that the core
residues for AAV-2 and AAV-3B are distinct. In AAV-3B, they are at
the mid-point between three adjacent spikes, while in AAV-2 they
occur on the side of each spike.
The gain-of-function mutants in AAV-3B have some interesting
implications. The S586R/T589R mutant combines the heparin binding
determinants of AAV-2 with those of AAV-3B, creating a chimeric
capsid with a broad receptor binding site and heparin binding afﬁnity
that is signiﬁcantly greater than any naturally occurring AAV
serotype. The apparent absence of such a “super-binding” variant in
nature suggests that selective pressure is not unimodally in the
direction of stronger receptor-binding. One might speculate that
overly tight binding might be a selective disadvantage in vivo if the
virus becomes non-productively sequestered in, for example,
heparanoid-rich connective tissue.
While the AAV-2 and AAV-3B heparin-binding sites can be
contrasted at a detailed level, there are fundamental similarities in
binding at sites in the vicinity of the three-fold spikes. Proximity to
the spikes could be providing partial protection of the binding site
from immune surveillance (Rossmann, 1989). Alternatively, generally
similar locations might, conceivably, result from a need to be near a
site important for a later step in cell entry or trafﬁcking. It is intrigu-
ing that within the constrained proximity to the spikes, the serotypes
have selected different positively charged amino acids to anchor their
core receptor interactions. One possible rationalization is that these
sites remain under at least some immune surveillance, and that
there has continued to be selective pressure to change residues
within an essential binding site where antibody binding might have
strong neutralizing potential.
The identiﬁcation of the receptor binding site on AAV-3B provides
new potential for its use as a therapeutic vector. Improved gene
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rationally, using insights from AAV structures and receptor binding
properties (Asokan et al., 2010; Shi and Bartlett, 2003; Shi et al.,
2006). Through its heparin binding site, it has been demonstrated
that the AAV-3B capsid can be modiﬁed to either to enhance or
reduce receptor binding, providing a novel template on which next
generation gene therapy vectors can be designed.
Materials and methods
Cell culture
HeLa cells were maintained in Joklik's Modiﬁed Essential Medium
(JMEM, Sigma-Aldrich) at 37 °C in 5% CO2. Medium was supplemen-
ted with 10% Cosmic Calf serum (HyClone, Inc.), 10 mg/L gentamicin,
and an antimicrobial cocktail containing 10 μg/mL penicillin, 50 mg/L
streptomycin, and 25 mg/L amphotericin (Gibco, Inc.). SF9 cells were
maintained in SF900-II medium (Invitrogen) in suspension at a cell
density of 0.5–2.0×106 cells/mL.
Plasmids and mutagenesis
Mutations were introduced into the AAV-3B capsid gene in the
pRepCap3B plasmid (Rutledge et al., 1998) using the QuikChange kit
(Stratagene) according to the manufacturer's protocol. pRepCap3B
contains the Rep and Cap genes of AAV-3B, but lacks the inverted
terminal repeats necessary for genome packaging.
AAV-3B virus-like particles (VLPs) produced in SF9 cells were used
as an ELISA standard. The AAV-3B capsid sequence was ampliﬁed
from pRepCap3B, introducing 5′ BglII and 3′ XbaI restriction sites.
Additional mutations to the 5′ end of the capsid gene were
introduced using the forward ampliﬁcation primer to improve the
capsid protein ratio in VLPs, as described (Urabe et al., 2002). The
insert was digested with BglII and XbaI (New England Biolabs) and
sub-cloned into the backbone of the pFBDVPm11 plasmid (obtained
from Robert Kotin and as previously described (Urabe et al., 2002)),
digested with BamHI and XbaI. The sequences of all plasmids used
were conﬁrmed by sequencing at the DNA Sequence Analysis Shared
Resource in the Molecular Microbiology and Immunology Depart-
ment at OHSU.
Preparation of AAV
Production of infectious AAV-2 and AAV-3B was performed as
previously described (Lerch et al., 2009; Xie et al., 2004). Production
of AAV-3B VLPs from SF9 cells followed methods used for production
of AAV-2 (Urabe et al., 2002) using the Bac-to-Bac Baculovirus
Expression Vector System (Invitrogen). VLPs were harvested from
SF9 cells by three rounds of freeze-thawing and puriﬁed by three
consecutive CsCl gradients, as described for infectious AAV puriﬁca-
tion (Xie et al., 2004).
For transfection of the pRepCap3B plasmids containing capsid
mutations, HeLa cells were plated at half conﬂuence in 30 mL JMEM
with 10% FCS per T-75 ﬂask 1 day prior to transfection. 30 μg of each
pRepCap3B plasmid per T-75ﬂaskwas transfectedwith 75 μL Lipofecta-
mine 2000 in OptiMEM medium (Invitrogen) according to the manu-
facturer's protocol. Six hours after transfection, medium was replaced
and adenovirus type 2 (Ad-2) at an MOI of 1 was added to the cells to
provide helper functions in AAV gene expression. 72 h post-
transfection, cells were harvested by scraping and pelleted by centrifu-
gation at 112,400×g (25,000 rpm) for 2 h using a Beckman SW28
ultracentrifuge rotor. Cell pellets were suspended in 1 mL PBS and
subjected to 3 rounds of freeze-thawing to lyse the cells. Cell debris
was clariﬁed by centrifugation at 5000×g for 10 min, and clariﬁed
lysates containing AAV-3B and mutant capsids were stored at−20 °C.
Wild-type and mutant AAV-3B capsid expression was analyzed byWestern blot, probing with a monoclonal antibody (MAb) speciﬁc for
denatured capsids (B1, American Research Products, Inc.), and the ap-
propriate ratio of capsid proteins was conﬁrmed. Proper assembly of
capsids was conﬁrmed by dot blot, probedwithMAb A20, which is spe-
ciﬁc for intact capsids (Wobus et al., 2000).
Transducing vectors based on WT and the R594A mutant AAV-3B
capsid were prepared in the Vollum Viral Core at OHSU using the
triple transfection method described previously (Ayuso et al., 2010).
Vectors containing a GFP reporter gene (driven by a CMV promoter
and ﬂanked by AAV-2 inverted terminal repeats) were puriﬁed from
the cell medium by PEG precipitation, followed by a single centrifuga-
tion gradient in CsCl. Vectors were exchanged into PBS in micro-
concentrators (Amicon) and titers (vector genomes/mL (vg/mL))
were determined by quantitative PCR.
Crystallization and data collection
Crystals of infectious AAV-3B in complex with the heparin analog
sucrose octasulfate (SOS) were grown by the hanging-drop vapor
diffusion method at room temperature. 2 μL of puriﬁed infectious
AAV-3B (concentrated to 6 mg/mL in 100 mM HEPES, 50 mM MgCl2,
pH7.4) was mixed with 2 μL of a well solution containing 1.3% PEG
6000, 225 mM NaCl and 1 mM SOS. Crystals grew to ~300 μm in
3–4 weeks. Crystals were harvested by adding a harvest buffer (5%
PEG 6000, 200 mM NaCl, 100 mM HEPES pH7.5, 50 mM MgCl2, 1 mM
SOS) to the crystallization drop and subsequently cryo-protected by
soaking for 1–5 min in harvest buffer that contained 10% PEG 6000
(total concentration) and 30% glycerol prior to ﬂash-freezing in liquid
nitrogen.
Diffraction data were collected at the BioCARS 14-BM-C beamline
at the Advanced Photon Source, Argonne, IL. Crystals were exposed
to 0.979 Å (12,668 eV) synchrotron radiation for 15 s with 0.5° oscilla-
tions. To obtain adequate diffraction spot separation, the detector was
positioned 600 mm from the crystal, with a beam stop 100 mm from
the crystal and the X-ray source was focused 400 mm from the
sample. Reﬂection intensities were indexed, integrated and scaled
using HKL 2000 (Otwinowski and Minor, 1997).
Diffraction data to 6.5 Å resolution were collected from the best
crystal. 187 frames were obtained, and the data were 99.9% complete
with 19-fold redundancy. Despite strong reﬂections (b I>/
bσI>=7.5) in the highest resolution shell (6.61–6.5 Å), the intensi-
ties of reﬂections at higher resolution decreased sharply, preventing
their use in structure determination. The data were processed in the
space group F4132 (which is different from the native AAV3B crys-
tals) with an Rmerge of 16.9%. The 2.6 Å structure of AAV-3B (PDB ID
3KIC; (Lerch et al., 2010)) was used to determine the position and
orientation of the virus in the unit cell. A pentamer of viral subunits
(1/12th of the capsid) is contained in the asymmetric unit. The
position and orientation of the virus are ﬁxed, as the 32 crystallo-
graphic and icosahedral symmetry axes are co-incident. Thus, the
virus particle, centered at the origin of the unit cell, was positioned
by aligning one 3-fold and two 2-fold icosahedral symmetry axes
with those of the unit cell. Bulk solvent scaling was performed in
Phenix (Adams et al., 2002), and electron density map averaging
was performed using Rave (Kleywegt et al., 2004).
Capsid titer
The concentration of AAV capsids in clariﬁed HeLa cell lysates was
determined by sandwich ELISA (Grimm et al., 1999). Capsid ELISAs
were performed as described, except that 0.5% BSA (Jackson
ImmunoResearch) was used as a blocking agent, and streptavidin-
conjugated horse radish peroxidase (R&D Systems, Inc) and 1-Step
Ultra TMB-ELISA Substrate (Pierce) were used in development.
AAV-3B VLPs puriﬁed from SF9 cells were used as a standard for
concentration determination.
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Heparin binding was analyzed by afﬁnity chromatography using a
1 mL HiTrap Heparin HP column (GE Healthcare). Puriﬁed infectious
AAV-2 or AAV-3B or clariﬁed HeLa cell lysates containing 200–
500 ng AAV mutant capsids were loaded onto the column after ﬁrst
washing with 5 M NaCl and equilibrating with 10 column volumes
(CV) of PBS. Unbound capsids were washed from the column with 5
CV PBS, collected over 3 fractions. Capsids were eluted from the
column in 1 CV steps using PBS supplemented with additional NaCl.
For capsid mutants with greater afﬁnity than WT AAV-3B, 100 mM
NaCl increments were used (PBS+0.1–1.0 M NaCl). For mutants
that bound to the column more weakly than WT AAV-3B, a ﬁne
step-gradient of 25 mM NaCl increments was used (PBS+25–
500 mM NaCl). Flow-through (FT), wash, and elution fractions were
analyzed by an AAV capsid ELISA (Grimm et al., 1999).
Cell binding and transduction
Cell binding assays followed methods previously used for AAV-2
(Kern et al., 2003). HeLa cells were plated in 96-well culture plates
(BD Falcon) at half-conﬂuence 1 day before cell binding was mea-
sured. AAV capsids were diluted in ice-cold PBS and incubated with
cells that had also been cooled to 4 °C. Infectious AAV-3B and AAV-2
were measured in 2-fold serial dilutions from 10 μg/mL-20 ng/mL,
and AAV-3B mutant capsids were compared at 150–300 ng/mL. Incu-
bation of capsids on cells was carried out at 4 °C for 1 h, and cells were
washed twice with chilled PBS. Cells were ﬁxed in methanol for
20 min at −20 °C and washed in PBS+0.05% Tween-20. Bound cap-
sids were detected with the AAV capsid ELISA procedure described
above (Grimm et al., 1999).
For cell transduction assays, HeLa cells were plated in 48-well
culture plates (BD Falcon) at half-conﬂuence 1 day before transduc-
tion. AAV-3B vectors were diluted in Dulbecco's Modiﬁed Eagle
Medium (DMEM), supplemented with 2% FBS, and added to cells at
100–1000 vg/cell. 48 h after addition of vectors, cells were analyzed
for GFP expression. At least 6 independent ﬁelds of cells expressing
GFP were counted, and transduction efﬁciencies (calculated as the
number of vector particles required for one transduction event)
were determined by correcting for the number of genome-
containing particles and total number of cells.
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